Post-diagnosis weight gain over ~1.5 years is consistently associated with increased breast cancer–specific and all-cause mortality across meta-analyses. How GLP-1 weight-loss drugs fit after breast ...

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

At the 2026 Miami Breast Cancer Conference, Kevin Kalinsky, MD, MS, participated in a molecular tumor board session that brought together a multidisciplinary panel including medic ...

Ipsen initiated an immediate, worldwide withdrawal of the EZH2 inhibitor tazemetostat across follicular lymphoma and epithelioid sarcoma due to emerging safety signals. An independent data monitoring ...

Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...

Thirty-six progressive mCRPC patients received TLX591-Tx across three cohorts (enzalutamide, abiraterone, or docetaxel sequence), and all completed two planned doses without emergent, unexpected ...

Effectively assessing anemia in myelofibrosis goes beyond hemoglobin levels, and should focus on symptoms, daily function, and quality of life to guide treatment. In a recent discussion, Raajit Rampal ...

Academic-center care was independently associated with higher complete oncologic resection rates and improved overall survival versus nonacademic facilities after adjustment for age, comorbidity, and ...

The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...

The randomized, double-blind, placebo-controlled, multicenter study enrolled 992 patients globally. The intent-to-treat ...

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...